Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

Research output: Contribution to journalArticlepeer-review


  • M Law
  • T Maruyama
  • J Lewis
  • E Giang
  • AW Tarr
  • P Gastaminza
  • FV Chisari
  • IM Jones
  • RI Fox
  • JK Ball
  • NM Kneteman
  • DR Burton

Colleges, School and Institutes


A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.


Original languageEnglish
Pages (from-to)25-27
Number of pages3
JournalNature Medicine
Issue number1
Publication statusPublished - 1 Jan 2008